Michael Weickert, Ph.D.
Michael Weickert has extensive experience as a CEO (7 yrs; Sonescence, SEA Medical) and entrepreneurial leader (CBO, VP) in biotechnology (Somatogen), drug delivery (Inhale, Nektar, Strategent Life Sciences, Corium, Sonescence, SciDose LLC), medical devices (SEA Medical) and pharmaceuticals (Ligand, Auspex), including raising capital, establishing and maintaining business partnerships, and leading new ventures. He personally initiated and negotiated investment rounds (Seed through Series C) and partnerships worth more than $175 Million. Michael prepared dozens of business plans and marketed programs to partners in the US and internationally (Japan, Germany, United Kingdom, Switzerland, Italy, and Israel). He has driven pharmaceutical product development through all clinical phases and engaged with the FDA and EMEA on regulatory requirements, Orphan Drug and Fast Track designations. He created an anti infectives business unit for Nektar that placed four products in development and formed the core of the $115M pulmonary business acquisition by Novartis in 2008. At Wit Creek Partners, Dr. Weickert has prepared business and marketing plans for a Nobel Prize winner’s startup and several other Venture backed startups and for public companies, and led development of pharmaceutical and drug delivery products.
Dr. Weickert served on the screening committee for Devices and for Therapeutics for seven years with Life Science Angels, a premier Angel group in the Bay Area. He received his Ph.D. in Genetics from the University of Wisconsin and worked at the National Cancer Institute of NIH. Dr. Weickert is currently an advisor for several companies. He holds numerous biotechnology and device patents and has published many scientific papers in leading journals.
His public profile and endorsements are available at: http://www.linkedin.com/in/weickert.
Examples of work and engagements can be viewed at: www.witcreek.com